爾康製藥(300267.SZ)擬5800萬元收購武陟維爾康100%股權 推進公司“原輔料+製劑”一體化商業生態
格隆匯5月8日丨爾康製藥(300267.SZ)公佈,2020年5月8日,公司第四屆董事會第七次會議、第四屆監事會第七次會議審議通過《關於收購武陟維爾康生化製藥有限公司100%股權暨關聯交易的議案》,公司擬與關聯方河南豫興康製藥有限公司(“豫興康”)簽署《股權收購協議》,擬使用自有資金5800萬元收購豫興康持有的武陟維爾康生化製藥有限公司(“武陟維爾康”)100%股權。此次股權收購有利於進一步豐富公司原料藥及成品藥品種,完善產品結構,拓展客户羣體,擴大市場規模,培育新的業績增長點,推進公司“原輔料+製劑”一體化商業生態。
武陟維爾康生化製藥有限公司經營範圍:生產、銷售:小容量注射劑、凍乾粉針劑、片劑、硬膠囊劑、散劑、原料藥(輔酶A、聚肌苷酸、聚胞苷酸、胰激肽原酶、三磷酸胞苷二鈉)(有效期以許可證為準);房屋租賃。
武陟維爾康擁有輔酶A、胰激肽原酶、門冬酰胺酶、三磷酸胞苷二鈉等9個原料藥品種,擁有注射用輔酶A、注射用胰激肽原酶、注射用門冬酰胺酶、注射用三磷酸胞苷二鈉等59個成品藥批文。
公司此次收購武陟維爾康100%股權,有利於進一步豐富公司原料藥及成品藥品種、完善原料藥產品結構,增加公司OTC產品管線,優化市場佈局,有利於擴大公司市場規模、培育新的業績增長點,推進公司“原輔料+製劑”一體化商業生態。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.